UN REPORT SU BB BIOTECH


LONDON, September 5 (newratings.com) – Analyst Holger Blum of Deutsche Bank reiterates his "buy" rating on BB Biotech (BIO.ZRH). The target price has been raised from CHF116.50 to CHF119.In a research note published this morning, the analyst mentions that the company's NAV has risen by 10.6% year-to-date, outperforming the Nasdaq biotech index. This spectacular performance, despite volatile market conditions, is on account of BB Biotech's conservative stock-picking policy, which focuses on advanced biotech companies, the analyst says. The company's stock might exceed its year-to-date trading range of CHF90-CHF100, particularly if newsflow related to the main companies in the sector stays positive, Deutsche Bank adds.

Non accontentarti solo degli articoli Free!

Registrati gratuitamente e avrai accesso senza limitazioni ai servizi premium per 7 giorni!